Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has announced successful clinical trial data showcasing the effectiveness of RAD 101 (18F-Pivalate) in detecting brain metastases using a novel PET-mpMRI imaging approach. This breakthrough demonstrates a high tumor-to-background ratio, promising a more sensitive detection method compared to the current standard of care, and could significantly improve diagnostic accuracy for suspected recurrent brain metastases. The ongoing Phase 2b trial in the United States aims to further evaluate the diagnostic performance of RAD 101, potentially enhancing the company’s positioning in the oncology radiopharmaceutical market.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company specializing in the development of innovative radiopharmaceutical products for both diagnostic and therapeutic applications, particularly in areas with high unmet medical needs. The company is publicly listed on the ASX and Nasdaq, with a diverse pipeline of molecules including peptides, small molecules, and monoclonal antibodies targeting a variety of solid tumors such as brain, lung, breast, and pancreas.
YTD Price Performance: 25.00%
Average Trading Volume: 9,805,509
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$58.35M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.
